NCT05932277View on ClinicalTrials.gov

A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 29, 2023

Primary Completion Date

September 13, 2023

Study Completion Date

September 13, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

BMS-986419

Specified dose on specified days

DRUG

Caffeine

Specified dose on specified days

DRUG

Bupropion

Specified dose on specified days

DRUG

Flurbiprofen

Specified dose on specified days

DRUG

Omeprazole

Specified dose on specified days

DRUG

Midazolam

Specified dose on specified days

DRUG

Fexofenadine

Specified dose on specified days

Trial Locations (1)

66219

ICON Lenexa, Lenexa

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY